RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out what effects RAD001 has on angiomyolipomas
of a person with Tuberous Sclerosis Complex and to determine the safe dose of RAD001 without
toxicity.
The hypothesis is that the drug will inhibit the growth of the angiomyolipomas and possibly
even cause regression.